

## PRESS RELEASE

**innate** pharma

---

### **INNATE PHARMA ANNOUNCES ITS PARTICIPATION TO THE "LIFE SCIENCE DAY"**

November 9, 2010, Paris, France

**Marseilles, France, November 5, 2010**

---


Innate Pharma (the "Company" - Euronext Paris: FR0010331421 – IPH) announces today that it will participate to the "Life Science Day", a conference organized by NYSE-Euronext and France Biotech, and dedicated to meetings between biotechnology companies listed on NYSE-EURONEXT and investors. This day will take place on November 9, 2010, in Paris, France.

During this event, Hervé Brailly, CEO of Innate Pharma, will present the Company, its development strategy and its latest news.

Innate Pharma will also participate to the coming investor conferences:

- "Healthcare & Biotechnology Conference" organized by Société Générale, in Paris on February 9, 2011
- "CF&B Smallcap Event", in Paris on April 25 and 26, 2011

Innate Pharma is committed to meet on a regular basis with the financial community. Investors can also find updated information on the company's website ([www.innate-pharma.com](http://www.innate-pharma.com)) and contact the investor relations team by writing to [investors@innate-pharma.com](mailto:investors@innate-pharma.com).



## PRESS RELEASE

innate pharma

---

### About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. It has two proprietary clinical-stage drug candidates: IPH 1101, a small molecule agonist of gamma delta T cells, has achieved proof-of-concept in two Phase IIa trials, in Type C Viral Hepatitis and follicular Lymphoma. IPH 2101, an anti-KIR monoclonal antibody potentiating NK cells activation, is currently in Phase II clinical trials in hematologic cancers. Innate Pharma also develops a preclinical portfolio of immunomodulatory or cytotoxic monoclonal antibodies. Two of its preclinical programs in chronic inflammation are out-licensed to Novo Nordisk A/S.

The key expertise of Innate Pharma is in immuno-pharmacology and antibody technology. The Company has implemented in-house a large panel of molecular and cellular assays and in vivo models for assessment of pharmacodynamics and pharmaco-toxicology of drug candidates. In addition, Innate Pharma has access to a very large set of unique research tools in cellular immunology through its worldwide network of scientific collaborations.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in Marseilles, France, and had 84 employees as at September 30, 2010. Learn more about Innate-Pharma at [www.innate-pharma.com](http://www.innate-pharma.com).

### Practical Information about Innate Pharma shares:

**ISIN code** FR0010331421  
**Ticker code** IPH

### Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website (<http://www.amf-france.org>) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

### For additional information, please contact:

**Innate Pharma**  
Laure-Hélène Mercier  
Director, Investor Relations  
Phone: +33 (0)4 30 30 30 87  
[investors@innate-pharma.com](mailto:investors@innate-pharma.com)

**Alize Public Relations**  
Caroline Carmagnol  
Phone: +33 (0)1 41 22 07 31  
Mobile: +33 (0)6 64 18 99 59  
[caroline@alizerp.com](mailto:caroline@alizerp.com)